Investor Presentation Q1FY23
The Biocon Value Creation Journey
An
2005-
2009
2010-
2015
2016-
2018
1978-
1999
2000-
2004
DOO
Enzymes
Company
2019 &
Beyond
Transforming
into a
Biopharma
Company
Building the Base
Business and
Expertise in
Biologics
Strategic Global
Alliance with Mylan
for Biosimilars
Expanded (2013)
Successful IPO,
Biocon listed in
India (2004)
Enzymes Business
Divested (2007)
Generic
Formulations
Global Development
Business Unit set up
(2013)
Commercialized
Biosimilars for
Diabetes &
Cancer in Japan,
U.S., EU
Global Partnership
with Sandoz for
Next-Gen
Biosimilars (2018)
Poised for
Global Impact
with
Biosimilars
Investments in
complex
Generic
Formulations
of Biosimilars in
Partnership with
Mylan (2009)
IPO of Syngene
(2015)
* Biocon
Unwavering focus through the years on research and innovation to create tangible differentiators for sustainable growth
BIOCON LIMITED 5View entire presentation